Universal CAR-T given to Second baby with aggressive Leukemia

09/05/2016 - 2 minutes

Once again, the French biotech Cellectis has hit headlines after having treated a second infant suffering from an aggressive form of Leukemia with their UCART19 therapy.

cellectis_ucart19_leukemia_trialAlso based at the famous Great Ormond Street Hospital (GOSH) in London, another child has been treated with the first ever Universal CAR-T cell therapy.

The child in question was diagnosed with a very aggressive form of leukemia at 4 weeks old. At aged 16 months, it became clear that she would be treated with UCART19 in December as a last resort.

However, given that UCART19 is still preparing for its Phase I trial (and therefore nowhere near market approval just yet), it is important to note that this particular success is another ‘compassionate care’ case, and UCART19 is not yet ready to be administered to other patients undergoing treatment.

 

UCART19 is a cell-based therapy (you can read more about in our review).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member